Evidence map›Paper›PMID 42433152›Full record

ReviewAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026

The Future of the HIV Response: Sustaining Progress in an era of Political Uncertainty and Scientific Opportunity.

Mitchell Warren

Abstract readReview
In one paragraph

Review in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Special Issue on New Horizons in HIV and Reproductive Health Research.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mitchell WarrenAIDS Vaccine Advocacy Coalition (AVAC), New York City, USA.ORCID https://orcid.org/0000-0003-3626-7156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global HIV response is at a pivotal juncture. The field is experiencing a paradox: rapid scientific innovation alongside increasing fragility in financing, political commitment, and implementation systems. Significant progress has been made in expanding access to HIV treatment and prevention, but major gaps in coverage and equity existed previously, that were further exacerbated and destabilized by changes in US government support in January 2025. This commentary examines the implications of this divergence and argues that the future of the HIV response depends less on new biomedical discoveries than on the capacity to deliver existing and emerging options sustainably and with speed, scale and equity. Drawing on recent advances in HIV prevention and treatment, as well as massive disruptions and cuts in both global health programs, including PEPFAR, and biomedical research funding under the new US Presidential Administration, the paper identifies key priorities for the next phase of the response, including strengthening health systems, ensuring equitable access, re-centering community leadership, and securing long-term political and financial commitments. Without decisive action, the gains of the past four decades risk stagnation or, worse, actual reversal; with it, the goal of ending the HIV epidemic may still be achievable.

Indexed as

HIV InfectionsBiomedical ResearchGlobal HealthHumansPoliticsUncertaintyUnited Statesglobal healthHIVimplementationinnovationNIHPEPFARPrEP

Identifiers

PMID42433152
PMCPMC13354972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.